@article{916b72462a1a40f6b70aac1dd9d42e40,
title = "The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis",
abstract = "To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.",
author = "Klassen, {Stephen A.} and Senefeld, {Jonathon W.} and Johnson, {Patrick W.} and Carter, {Rickey E.} and Wiggins, {Chad C.} and Shmuel Shoham and Grossman, {Brenda J.} and Henderson, {Jeffrey P.} and James Musser and Eric Salazar and Hartman, {William R.} and Bouvier, {Nicole M.} and Liu, {Sean T.H.} and Pirofski, {Liise anne} and Baker, {Sarah E.} and {van Helmond}, Noud and Wright, {R. Scott} and Fairweather, {De Lisa} and Bruno, {Katelyn A.} and Zhen Wang and Paneth, {Nigel S.} and Arturo Casadevall and Joyner, {Michael J.}",
note = "Funding Information: Grant Support: This work was supported by grants from the National Heart, Lung, and Blood Institute ( 5R35HL139854 to M.J.J.), the National Institute of Diabetes and Digestive and Kidney Diseases ( 5T32DK07352 to J.W.S. and C.C.W.), the Natural Sciences and Engineering Research Council of Canada ( PDF-532926-2019 to S.A.K.), the National Institutes of Health ( 1-F32-HL154320-01 to J.W.S.), the National Institute of Allergy and Infectious Diseases ( R21 AI145356 and R21 AI152318 to D.F.; R01 AI1520789 to A.C.), and the National Heart, Lung, and Blood Institute ( R01 HL059842 to A.C.). Publisher Copyright: {\textcopyright} 2021 Mayo Foundation for Medical Education and Research",
year = "2021",
month = may,
doi = "10.1016/j.mayocp.2021.02.008",
language = "English (US)",
volume = "96",
pages = "1262--1275",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Ltd",
number = "5",
}